000			02095 a2200529 4500
005			20250516095009.0
264		0	_c20121016
008			201210s 0 0 eng d
022			_a1095-6859
024	7		_a10.1016/j.ygyno.2012.06.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aChase, Dana M
245	0	0	_aChanges in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. _h[electronic resource]
260			_bGynecologic oncology _cSep 2012
300			_a375-80 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
650	0	4	_aAged
650	0	4	_aAngiogenesis Inhibitors _xpharmacology
650	0	4	_aAntibodies, Monoclonal, Humanized _xpharmacology
650	0	4	_aBevacizumab
650	0	4	_aBlood Vessels _xpathology
650	0	4	_aCarcinoma, Ovarian Epithelial
650	0	4	_aContrast Media
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMagnetic Resonance Imaging
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasms, Glandular and Epithelial _xblood supply
650	0	4	_aNeovascularization, Pathologic _xpathology
650	0	4	_aOvarian Neoplasms _xblood supply
650	0	4	_aPeritoneal Neoplasms _xblood supply
650	0	4	_aPredictive Value of Tests
650	0	4	_aRegional Blood Flow _xdrug effects
650	0	4	_aSingle-Blind Method
700	1		_aSill, Michael W
700	1		_aMonk, Bradley J
700	1		_aChambers, Mark D
700	1		_aDarcy, Kathleen M
700	1		_aHan, Ernest S
700	1		_aBuening, Barbara J
700	1		_aSorosky, Joel I
700	1		_aFruehauf, John P
700	1		_aBurger, Robert A
773	0		_tGynecologic oncology _gvol. 126 _gno. 3 _gp. 375-80
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2012.06.002 _zAvailable from publisher's website
999			_c21851512 _d21851512